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Abstract. Recurrent and/or metastatic head and neck 
squamous cell carcinoma (R/M HNSCC) is a devastating 
malignancy with a poor prognosis. According to recent 
clinical studies, tumour growth can be effectively reduced 
and survival can be improved by blocking the programmed 
death receptor-1 (PD-1)/programmed death-ligand 1 (PD-L1) 
pathway. PD-L1 expression has been proposed as a potential 
causative mechanism, as HNSCC is highly immunosuppres-
sive. However, anti-PD-1 treatment is beneficial only for certain 
patients. Therefore, the mechanisms controlling PD-L1 expres-
sion warrant further investigation in order to provide a better 
understanding of the predicting efficacy of and optimising 
anti-PD-1 therapy, alone or in combination. In this study, 
PD-L1 protein extracted from the cell membrane was found 
to be downregulated in OSC-20 cells compared with OSC-19 
cells, despite a higher PD-L1 expression in the total cell lysate 
of the OSC-20 compared with the OSC-19 cells. Several matrix 
metalloproteinases (MMPs) were found to be upregulated in 
HNSCC; in particular, MMP-7 and -13 were upregulated in 
the OSC-20 compared with the OSC-19 cells. Purified PD-L1 
was degraded by recombinant MMP-13 and -7. The expres-
sion of PD-L1 was significantly restored by a specific inhibitor 
of MMP-13 (CL82198), which suggested the involvement of 
MMP-13 in the shedding/cleavage of PD-L1 in the OSC-20 
cells. Among the anticancer drugs conventionally used in 
the treatment of patients with HNSCC, paclitaxel increased 
MMP-13 expression in R/M HNSCC cells (HOC313 cells) 
co-cultured without/with dendritic cells (DCs). These results 
suggest that the shedding/cleavage of PD-L1 by MMP-13 is 
one of the mechanisms behind the protective effect against 
invasion and metastasis. Thus, MMP-13 has potential value 
as a marker predictive of the decreased efficacy of anti-PD-1 
therapy. In addition, paclitaxel is a particularly promising 
candidate for combination therapy in R/M HNSCC with anti-
PD-1 therapy.
Introduction
Recurrent and/or metastatic head and neck squamous cell 
carcinoma (R/M HNSCC) is a devastating malignancy 
with a poor prognosis. Treatment is limited to chemothera-
peutic approaches. In recent studies, the programmed-death 
receptor-1 (PD-1 and CD279)/programmed-death ligand 1 
(PD-L1, B7-H1 and CD274) pathway has been indicated to 
be critical for regulating T-cell responses and maintaining 
immune suppression (1-4). HNSCC is a malignant tumour 
found most often in the head and neck region involving the 
mandibular gingiva and oral floor (5,6); it is generally highly 
immunosuppressive, for which PD-L1 expression has been 
proposed as a potential causative mechanism (7-9). In many 
tumours, expression of PD-L1 is constitutive and is induced 
by interferon-γ (IFN-γ). PD-L1 binds to an inhibitory 
receptor (PD-1), which is a member of the B7 family of recep-
tors (4), and to the co-stimulatory molecule, CD80 (B7-1) (10). 
PD-1 is expressed on activated T cells; when PD-1 ligates with 
tumour-associated PD-L1, the apoptosis or downregulation of 
effector cytotoxic T lymphocytes is induced, thereby resulting 
in an escape from T-cell-mediated immune surveillance (11). 
Tumour growth is reduced and survival is improved when the 
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PD-L1/PD-1 pathway is blocked (7,12-15). Moreover, clinical 
studies have indicated that tumour regression by the blockade 
of the PD-1/PD-L1 checkpoint is durable (1,2), leading to the 
recent registration of an anti-PD-1 antibody for head and neck 
cancer. In treated tumours, the response to the PD-1 blockade 
has been commonly been associated with PD-L1 expres-
sion (1).
However, anti-PD-1 treatment appears to be beneficial only 
in certain patients. Therefore, the mechanisms underlying 
the unknown regulation of PD-L1 expression in the HNSCC 
microenvironment remain to be elucidated. PD-L1 expression 
has been shown to be lower in R/M HNSCC cell lines than in 
a low-grade invasive and less metastatic HNSCC cell lines, 
and PD-L1 expression and epithelial-mesenchymal transi-
tion (EMT) have been found to be closely related (16). PD-L1 
expression has been shown to be upregulated in macrophages 
and dendritic cells (DCs) in human R/M HNSCC tissues or 
co-cultured with R/M HNSCC cells in vitro (16). However, 
the mechanisms responsible for the fact that PD-L1-expressing 
HNSCC cells exhibit low invasiveness and are less metastatic 
remain to be determined.
The immunosuppressive capacity of PD-1 ligands on 
fibroblasts may be limited by their matrix metallopro-
teinase (MMP)-dependent cleavage, thereby contributing to 
the aggravation of inflammation in tissues (17). Conversely, 
MMP activity seems to deplete PD-1 ligands in carcinoma-
associated fibroblasts, which may impair the physical deletion 
of exhausted defective memory T cells through apoptosis and 
may facilitate their regulatory functions (17). As MMPs are 
a group of proteolytic enzymes that can degrade principal 
components of the extracellular matrix, they are widely 
believed to play an important role in tissue degradation. Several 
sets of experimental and clinical data concerning MMPs in 
the contexts of cancer have been reported (18,19). Numerous 
MMP inhibitors have exhibited efficacy in animal models of 
disease and have been used in clinical trials in the treatment of 
cancer, with some studies focusing on rheumatoid arthritis and 
osteoarthritis. However, MMP inhibitors have not exhibited 
significant therapeutic effects in any of these human clinical 
trials (20). The use of these inhibitors also results in adverse 
effects, including musculoskeletal pain, tendonitis and mild 
anaemia with elevated liver enzyme levels (20). Therefore, 
the function of MMP needs to be redefined. MMPs influence 
basic processes, such as cell proliferation, differentiation, 
angiogenesis and apoptosis (18). Notably, the MMP family of 
proteins exert dual roles in the pathogenesis of inflammation: 
Stimulating protective innate and/or adaptive immune func-
tions, as well as tissue destruction (21).
To predict the efficacy of and optimise anti-PD-1 therapy, 
alone or in combination with other treatment options, it is 
important to elucidate the mechanisms controlling PD-L1 
expression. In this study, we thus focused on the regulation of 
PD-L1 expression in HNSCC, and discussed the mechanism 
of this regulation of PD-L1 expression in the tumour micro-
environment.
Materials and methods
Cell culture. Three HNSCC cell lines originally established 
from tumour biopsies with different grades of invasive or 
metastatic abilities were used, including OSC-20 cells (with 
low invasiveness), OSC-19 cells (intermediate invasiveness) 
and HOC313 cells (recurrent high-grade invasiveness and 
metastasis). The OSC-20 cell line was originally derived from 
a 58-year-old female with tongue cancer (22). OSC-19 was 
derived from a 61-year-old male with tongue cancer metastatic 
to the cervical lymph nodes (23). HOC313 was derived from 
a 51-year-old female with HNSCC (involving the mandibular 
gingiva and oral floor) that metastasised to the cervical 
lymph nodes and recurred (24). The HOC313 cells were a 
kind gift from Dr M. Nagayama (Tokushima University, 
Tokushima, Japan). The OSC-20 (JCRB #0197) and OSC-19 
(JCRB #0198) cells, and normal human oral fibroblasts of the 
lip mucosa (KD; JCRB #9103) were obtained from the JCRB 
Cell Bank (Osaka, Japan). DCs were generated from human 
peripheral blood mononuclear cells (PBMCs), as previously 
described (25,26). Experiments using human samples were 
approved by the Ethics Committee of the Kanazawa University 
Graduate School of Medical Science (IRB no. 352-2), 
and written informed consent was obtained from persons 
providing human samples. Peripheral blood was voluntarily 
donated by 3 healthy individuals. PBMCs were obtained by 
venepuncture into an 8-ml Vacutainer CPT Cell-Preparation 
Tube (BD Vacutainer Systems, Franklin Lakes, NJ, USA). 
Monocyte-derived DCs were generated by incubating mono-
cytes at 1x106 cells/ml in G4 medium (G4 Dendritic Cell 
Generation kit; HumanZyme, Chicago, IL, USA) at 37˚C 
in a CO2 (5%) incubator for 7 days. The induced DCs were 
examined using an anti-DC antibody (CD83; Abcam, Tokyo, 
Japan). Eribulin (also known as Halaven; HAL) was purchased 
from Eisai Co., Ltd. (Tsukuba, Japan). Vinblastine (VBL) and 
paclitaxel (PTX; Taxol) were purchased from Nihon Kayaku 
(Tokyo, Japan).
RNA extraction, cDNA synthesis and quantitative (real‑time) 
PCR (qPCR). The mRNA expression levels of PD-L1, and 
MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13 and -14 were anal-
ysed using a Rotor-Gene Q 2plex System (Qiagen, Hilden, 
Germany) with FAM/ZEN/IBFQ probes (Integrated DNA 
Technologies, Inc., Coralville, IA, USA; DNA sequences not 
available). Total RNA was extracted using the PureLink RNA 
mini kit (Thermo Fisher Scientific, Waltham, MA, USA), 
and cDNA was obtained using the PrimeScript First-Strand 
cDNA synthesis kit (Takara, Tokyo, Japan). All reactions were 
performed in accordance with the manufacturer's instruc-
tions. We amplified 18S rRNA as an internal standard using 
HEX/ZEN/IBFQ probes (Integrated DNA Technologies, Inc.; 
DNA sequences not available). Relative expression levels 
were calculated using the ΔΔCt method for qPCR (27), which 
presents the data as fold differences in expression level relative 
to a calibrator sample, in this case represented by the mean 
expression of 3 experimental measurements of 18S rRNA in 
the control cells or vehicle (buffer only control)-treated cells.
Western blot analysis. The concentration of total extracted 
protein was measured after 100-fold dH2O dilution by the 
Qubit Protein assay, in accordance with the manufacturer's 
instructions (Thermo Fisher Scientific). An equal amount 
(30 µg of protein) of lysate or culture medium was mixed with 
loading buffer, with this mixture then being electrophoretically 
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separated and transferred onto membranes. The membranes 
were blocked with Blocking One (Nacalai Tesque, Kyoto, 
Japan), followed by incubation with anti-PD-L1 or MMP-7, 
-12, -13 antibodies (PD-L1, cat. no. 210931; MMP-7, cat. 
no. 205525; MMP-12, cat. no. 52897; MMP-13, cat. no. 51072; 
Abcam) and an anti-human β-actin antibody (cat. no. 4970; 
Cell Signaling Technology, Tokyo, Japan). After washing with 
Tris-buffered saline (TBS) with 0.05% Tween, the membranes 
were incubated with horseradish peroxidase-conjugated 
anti-mouse IgG. After washing with TBS-0.05% Tween-20, 
membranes were incubated with the ECL Prime Western 
Blotting Detection Reagent (GE Healthcare, Little Chalfont, 
UK). Signals were detected and analysed using C-DiGit 
(M&S TechnoSystems, Tokyo, Japan).
Enzyme‑linked immunosorbent assay (ELISA). The 
membrane-associated proteins were extracted separately from 
the cytosolic proteins using the Mem-PER Plus Membrane 
Protein Extraction kit (Thermo Fisher Scientific). The extracted 
membrane-associated proteins were analysed for the presence 
of PD-L1 using the ELISA kit (cat. no. DY156; R&D Systems 
Europe Ltd., Abingdon, UK), in accordance with the manu-
facturer's instructions. The total membrane-associated protein 
concentration of the sample was measured by the Qubit 
Protein assay in accordance with the manufacturer's instruc-
tions (Thermo Fisher Scientific). Values were calculated as 
pg/mg total protein or ng/mg total protein. Data are presented 
as the means ± standard error of the mean (SEM).
Expression and purification of recombinant human PD-L1. 
Human PD-L1 cDNA (cat. no. RDC1087) was purchased from 
R&D Systems Europe Ltd. The human PD-L1 coding sequence 
and 6xHis-Tag were fused using PCR and the InFusion HD 
kit (Takara Bio) combined with pSG5 (Agilent Technologies 
Japan, Tokyo, Japan) to construct the expression plasmid 
pSG-hPDL1-His. The sequence was confirmed by sequencing.
The Expi293 cells were cultured in Expi293 Expression 
Medium (both from Thermo Fisher Scientific) and transfected 
with the pSG-hPDL1-His using FuGENE 6 transfection reagent 
(Promega, Tokyo, Japan). The culture media were harvested 
at 6 days after transfection and used for purification. They 
were concentrated using an Amicon Diaflo apparatus fitted 
with a YM-10 membrane (both from Merck Japan, Tokyo, 
Japan) and applied to complete His-Tag Purification Resin 
(Roche Diagnostics, Basel, Switzerland) equilibrated with 
50 mM Tris-HCl (pH 7.5), 0.15 M NaCl and 0.05% Brij 35. 
Recombinant human PD-L1 was eluted with 500 mM imid-
azole in 50 mM Tris-HCl (pH 7.5) buffer after washing the 
column with 50 mM Tris-HCl (pH 7.5) buffer containing 5 mM 
imidazole and 0.3 M NaCl. The combined fractions of human 
PD-L1 were dialysed against 50 mM Tris-HCl (pH 7.5), 0.15 M 
NaCl and 0.05% Brij 35 buffer to remove imidazole. The 
protein concentration was determined using the Qubit Protein 
assay, in accordance with the manufacturer's instructions 
(Thermo Fisher Scientific). Eluted fractions containing a major 
species of Mr 56,000 and minor protein bands of Mr 46,000 
were used as the source of PD-L1. Both minor species were 
recognised by an anti-PD-L1 antibody (PD-L1, cat. no. 210931; 
Abcam), while only major species were recognised by an anti-
His antibody (cat. no. D291-3; MBL, Tokyo, Japan).
Degradation of PD-L1 by MMP-13 and -7. The digestion of 
PD-L1 was examined by incubation of the purified PD-L1 at 
37˚C for 24 h with MMP-13 or -7 at an enzyme/substrate molar 
ratio of 1:30 in 50 mM Tris-HCl (pH 7.5), 0.15 M NaCl, 10 mM 
CaCl2 and 0.05% Brij 35 (TNCB buffer). Human recombinant 
MMP-13 (cat. no. 444287) and MMP-7 (cat. no. CC1057) were 
purchased from Merck Japan. MMPs were activated by incu-
bation with p-aminophenylmercuric acetate (Merck Japan), in 
accordance with previously reported methods (28,29). These 
reactions were terminated with 20 mM ethylenediaminetet-
raacetic acid (EDTA) and the degradation products were 
examined by western blot analysis using anti-PD-L1 antibody 
(PD-L1, cat. no. 210931; Abcam).
Inhibition of PD-L1 cell surface degradation in HNSCC cells. 
For the incubation of HNSCC cells with MMP inhibitors, the 
HNSCC cells were seeded at a concentration of 5x104 cells/cm2 
in P6 plates in DMEM medium (Sigma-Aldrich Japan, Tokyo, 
Japan) supplemented with 5% FCS and were then incubated on 
day 1 in the presence or absence of 2 MMP inhibitors (10 µg/ml 
CL82198, cat. no. 141576; and 10 µM BB94, cat. no. 142087; 
Abcam) and maintained in culture for 4 days at 37˚C without a 
medium change. Subsequently, membrane-associated proteins 
were extracted separately using the Mem-PER Plus Membrane 
Protein Extraction kit (Thermo Fisher Scientific). The extracted 
membrane-associated proteins were analysed for the presence 
of PD-L1 using the ELISA kit (cat. no. DY156; R&D Systems 
Europe Ltd.), in accordance with the manufacturer's instruc-
tions. The total protein concentration of the sample was 
measured after 100-fold dH2O dilution using the Qubit Protein 
assay, in accordance with the manufacturer's instructions 
(Thermo Fisher Scientific). Values were calculated as pg/mg 
total protein or ng/mg total protein. The PD-L1 expression 
recovery (%) was expressed as follows: Ratio (%) = difference 
between the amount of PD-L1 in HNSCC cells incubated in 
the presence of MMP inhibitors on day 4 and the amount of 
PD-L1 in HNSCC cells in the absence of MMP inhibitors on 
day 4/the difference between the amount of PD-L1 in HNSCC 
cells in the absence of MMP inhibitors on day 1 and the 
amount of PD-L1 in HNSCC cells in the absence of MMP 
inhibitors on day 4 x100.
Statistical analysis. For comparisons between samples, data 
were analysed by ANOVA and Tukey's multiple comparison 
tests using SPSS, version 23 software (IBM SPSS Statistics, 
IBM Corp., NY, USA). A P-value ≤0.05 or less was accepted 
as statistically significant.
Results
PD-L1 expression in HNSCC cell lines and cell surface PD-L1 
degradation in OSC‑20 cell lines. As shown in Fig. 1A, qPCR 
revealed that PD-L1 mRNA expression was upregulated in 
the OSC-20 and OSC-19 cells compared with that in the KD 
cells. Among these 3 HNSCC cell lines, the PD-L1 mRNA 
expression level ranged from 1.7- to 4.5-fold higher than that in 
KD cells (Fig. 1A). PD-L1 protein extracted from the total cell 
lysate was also upregulated in the OSC-20 and OSC-19 cells 
compared with the level in the HOC313 and KD cells, as deter-
mined by western blot anaysis (Fig. 1B). However, the amount 
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of PD-L1 protein extracted from the OSC-20 cell membrane 
(22.3-fold higher than that in the KD cells) was less than that 
of PD-L1 protein from the OSC-19 cell membrane (96.08-fold 
higher than that in KD cells) (Fig. 1C). PD-L1 protein in the 
culture supernatant from the OSC-20, OSC-19, HOC313 and 
KD cells was not detected by ELISA (data not shown).
MMP expression in HNSCC cell lines (OSC-20, OSC-19 
and HOC313). As shown in Fig. 2A, qPCR was used to 
determine MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13 and -14 
mRNA expression in the OSC-20, OSC-19, HOC313 and KD 
cells. The expression levels of MMP-7, -10, -12 and -13 in the 
OSC-20 cells were 2801.5-, 41.57-, 513.7- and 2522.2-fold 
higher than those in the KD cells, respectively. Moreover, 
the expression levels of MMP-9, -10 and -13 in the OSC-19 
cells were 317.6-, 38.6- and 1380.7-fold higher than those in 
the KD cells, respectively. MMP-3 expression in the HOC313 
cells was also 7.82-fold higher than that in KD cells. Overall, 
MMP expression in the HOC313 cells was not markedly high 
compared with the levels in the OSC-20 and OSC-19 cells. 
Among these MMPs that were upregulated in these HNSCC 
cells, the expression of MMP-7, -12 and -13 in particular was 
markedly upregulated in the OSC-20 cells compared with that 
in the OSC-19 cells. As shown in Fig. 2B, western blot analysis 
revealed that MMP-7 and -13 protein expression levels in the 
culture supernatant were upregulated in the OSC-20 cells 
compared with those in the OSC-19 cells. MMP-12 protein 
expression was negligible (Fig. 2B).
Purification and digestion of PD-L1 by recombinant MMP-7 
and MMP-13. PD-L1 purified from the culture medium of 
Expi293 cells transfected with the human PD-L1 expression 
vector contained a major protein band of Mr 56,000 and a 
minor band of Mr 46,000 (Fig. 3A), both of which were recog-
nised by anti-PD-L1 antibody. However, only the major species 
of Mr 56,000 was recognised by anti-His antibody. These find-
ings suggested that the species of Mr 46,000 was generated by 
C-terminal truncation of the species of Mr 56,000.
As shown in Fig. 2, MMP-7 and MMP-13 expression was 
upregulated in the OSC-20 cells, in which PD-L1 cell surface 
degradation was enhanced, and MMP-12 protein expression 
was negligible (Fig. 2B). Although MMP-12 mRNA was 
upregulated in the OSC-20 cells, the absolute amount of 
mRNA may be low. These results suggested that MMP-7 and 
MMP-13 were the candidates of proteinases involved in PD-L1 
degradation. Recombinant MMP-7 and MMP-13 were acti-
vated by incubation with p-aminophenylmercuric acetate, in 
accordance with previously described methods (28,29). PD-L1 
was digested for 24 h with MMP-7 or -13, and the digestion 
fragments were examined by western blot analysis. MMP-7 
and -13 degraded PD-L1 successfully as the amounts of PD-L1 
species of Mr 56,000 and 46,000 were reduced (Fig. 3B). The 
digested fragments of PD-L1 were not recognised by the anti-
PD-L1 antibody.
Inhibition of PD-L1 cell surface degradation in HNSCC cells. 
To determine which MMP contributes to PD-L1 degradation in 
HNSCC cells, we used MMP inhibitors with different speci-
ficities. As shown in Fig. 4, only the MMP-13-specific inhibitor 
(CL82198) significantly (P<0.05) restored PD-L1 expression in 
Figure 1. Expression and cell surface degradation of programmed 
death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma (HNSCC) 
cell lines. (A) Relative mRNA expression levels of PD-L1 in the OSC-20, 
OSC-19, HOC313 and KD cell lines. Expression levels are displayed as fold 
differences relative to control cells (KD cells). Each data point represents the 
mean of 3 independent experiments. The vertical bars show standard devia-
tions. Error bars correspond to SEM. *P<0.05 vs. control KD cells. (B) PD-L1 
protein extracted from the total cell lysate of OSC-20, OSC-19, HOC313 and 
KD cells was assessed by western blot analysis. The arrow indicates PD-L1. 
β-actin was detected as a loading control. (C) The amount of PD-L1 protein 
extracted from the cell membrane lysate of OSC-20, OSC-19, HOC313 and 
KD cells was measured by enzyme-linked immunosorbent assay (ELISA). 
Expression levels are displayed as fold differences relative to control cells 
(KD cells). Each data point represents the mean of 3 independent experi-
ments. The vertical bars show standard deviations. Error bars correspond to 
SEM. *P<0.05 vs. OSC-19 cells.
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Figure 2. Matrix metalloproteinase (MMP) expression in head and neck squamous cell carcinoma (HNSCC) cell lines (OSC-20, OSC-19 and HOC313). 
(A) Relative mRNA expression levels of MMP-1, -2, -3, -7, -8, -9, -10, -11, -12, -13 and -14 in the OSC-20, OSC-19, HOC313 and KD cell lines. Expression levels 
are displayed as fold differences relative to control cells (KD cells). Each data point represents the mean of 3 independent experiments. The vertical bars show 
standard deviations. Error bars correspond to SEM. *P<0.05 vs. OSC-19 cells. (B) MMP-7, -12 and -13 proteins in the culture supernatant of OSC-20, OSC-19, 
HOC313 and KD cells were assessed by western blot analysis. The arrows indicate MMP-7, -12 and -13. β-actin was detected as a loading control.
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the OSC-20 cells (23.2±5.1% recovery from day 1 to 4 in the 
presence of 10 mg/ml CL82198) when compared with the BB94 
inhibitor. PD-L1 expression was also significantly (P<0.05) 
restored by CL82198 in the OSC-19 cells (9.1±3.2% recovery 
from day 1 to 4 in the presence of 10 mg/ml CL82198). BB94 
did not restore PD-L1 expression in the HNSCC cells.
Tubulin inhibitor increased MMP-13 expression in R/M 
HNSCC cells (HOC313 cells) co-cultured with DCs. The 
results shown in Fig. 4 suggest that MMP-13 plays a key role 
in the shedding/cleavage of PD-L1. We wished to deterimine 
which anti-head and neck cancer drug would successfully 
upregulated MMP-13 expression. For this purpose, we used 
tubulin inhibitors (HAL, PTX and VBL) that are generally 
used in the treatment of head and neck cancer. As shown 
in Fig. 5A-C, following treatment of the OSC-20, OSC-19 and 
HOC313 cells with tubulin inhibitors, the PD-L1 and MMP13 
expression levels were analysed. MMP-13 expression was 
significantly downregulated in the HAL-treated OSC-20 and 
OSC-19 cells. Moreover, the MMP-13 and PD-L1 expression 
levels were significantly downregulated in the VBL-treated 
OSC-19 cells. No tubulin inhibitor used in the OSC-20 and 
OSC-19 cells increased MMP-13 expression (Fig. 5A and B). 
Only treatment with PTX upregulated MMP-13 expression 
in the HOC313 cells when compared with the other tubulin 
inhibitors used (Fig. 5C). No tubulin inhibitor used to treat 
the HOC313 cells altered the expression level of PD-L1. As 
shown in Fig. 5D, we examined the effects of tubulin inhibitor 
Figure 4. Inhibition of programmed death-ligand 1 (PD-L1) cell surface 
degradation in head and neck squamous cell carcinoma (HNSCC) cells. 
Recovery (%) of PD-L1 on HNSCC cells after 4 days of culture in the pres-
ence of matrix metalloproteinase (MMP) inhibitors. After 1 day of culture at 
37˚C, HNSCC cells were further cultured for 4 days at 37˚C in the presence or 
absence of MMP inhibitors (without any medium change). Cell surface PD-L1 
was extracted and measured by enzyme-linked immunosorbent assay (ELISA) 
on days 1 and 4. Each data point represents the mean of 3 independent experi-
ments. The vertical bars show standard deviations. Error bars correspond to 
SEM. *P<0.05 vs. BB94-treated OSC-20 and OSC-19 cells, respectively.
Figure 3. Purification and digestion of programmed death-ligand 1 (PD-L1) by recombinant matrix metalloproteinase-7 (MMP-7) and MMP-13. (A) Purified 
PD-L1 was analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) (silver staining, left panel) and western blot analysis (middle and 
right panels) using anti-PD-L1 or anti-His antibodies, respectively. Arrows indicate PD-L1 of Mr 56,000, and arrowheads indicate PD-L1 fragment of Mr 46,000. 
(B) PD-L1 was incubated with MMP-13 or 7 for 24 h at 37˚C. The reaction products were subjected to western blot analysis using anti-PD-L1 antibody after 
termination of the reaction with 20 mM ethylenediaminetetraacetic acid (EDTA). Arrows indicate PD-L1 and arrowheads indicate the PD-L1 fragment.
INTERNATIONAL JOURNAL OF ONCOLOGY  52:  379-388,  2018 385
on DCs co-cultured with HOC313 cells. Under co-culture 
conditions using DCs and HOC313 cells, treatment with 
PTX also upregulated MMP-13 expression when compared 
with the other tubulin inhibitors used. Treatment with HAL 
significantly upregulated PD-L1 expression in the HOC313 
cells co-cultured with DCs.
Discussion
PD-L1 is a ligand of the inhibitory receptor, PD-1, and the 
PD-1/PD-L1 pathway induces and maintains peripheral immu-
notolerance in cancer tissues (11,30). PD-L1 expression is 
constitutive in various types of human cancer, including squa-
mous cell carcinomas of the lung, oesophagus, and head and 
neck, as well as other types of carcinomas of the colon, ovaries, 
bladder and breast, and melanoma and glioma (7,12,13,30-38). 
Our previous study demonstrated that PD-L1 expression in 
HNSCC cell lines with low invasiveness (OSC-20 and OSC-19 
cells) was higher than that in the R/M HNSCC line (TSU 
cells) (16). These findings contradicted previous results for 
other tumour types (7,12,13,30-38). Although the molecular 
mechanisms underlying this difference remain unclear, we 
hypothesise that they are confined to cancer subtypes with a 
unique molecular profile. In this study, we demonstrated that 
PD-L1 mRNA and total protein expression was downregu-
lated in R/M HNSCC (HOC313 cells) and upregulated in cells 
with low invasiveness (OSC-20 and OSC-19). These findings 
are consistent with our previous results (16). Of note, in this 
study, PD-L1 protein extracted from the cell membrane was 
downregulated in OSC-20 cells compared with OSC-19 cells, 
despites higher PD-L1 expression in the total cell lysate of 
OSC20 cells compared with that in OSC-19 cells. These find-
ings suggested that PD-L1 could be degraded on the OSC-20 
cell surface by some proteinases.
A recent study from another group demonstrated that 
PD-L1 was cleaved by recombinant MMP-13 and MMP-9, 
which may limit the immunosuppressive capacity and 
may thus contribute to the exacerbation of inflammation 
in tissues (17). MMP family proteins are the most plausible 
PD-L1 degradation proteinases as they play dual roles in the 
pathogenesis of inflammation: Stimulating protective innate 
and/or adaptive immune functions, as well as tissue destruc-
tion (21). The results shown in Fig. 1 suggest that proteinases 
that were upregulated in OSC-20 may play a key role in the 
cell surface degradation of PD-L1. The results shown in Fig. 2 
suggest that several MMPs were upregulated on HNSCC, and 
in particular, MMP-7 and -13 were upregulated in OSC-20 cells 
rather than in OSC-19 cells. On the other hand, the OSC-19 
cells exhibited a significant upregulation in MMP-9. Indeed, 
MMP-9 may play important roles in the invasion and metas-
tasis of cancer cells (39-41). However, MMP-9 inhibitors did 
not exert a significant therapeutic effect in any of these human 
clinical trials (20). Recent studies have shown a protective role 
of MMP-9 in carcinogenesis, tumour growth or metastasis, 
in experiments using MMP-9 KO mice (42,43); however, the 
detailed mechanisms behind this protective effect remain 
unclear. The results from the present study demonstrated 
that PD-L1 shedding in OSC-19 cells was less than that in 
the OSC-20 cells. We hypotheised that the shedding/cleavage 
of PD-L1 by MMP-9 was not the main mechanism behind 
Figure 5. Tubulin inhibitor increases matrix metalloproteinase-13 (MMP-13) 
expression on R/M head and neck squamous cell carcinoma (HNSCC) cells 
(HOC313 cells) co-cultured without/with dendritic cells (DCs). Relative 
mRNA expression levels of MMP-13 and programmed death-ligand 1 (PD-L1) 
in the (A) OSC-20, (B) OSC-19 and (C) HOC313 cell lines treated with 
tubulin inhibitor (HAL, eribulin; PTX, paclitaxel; and VBL, vinblastine). 
Expression levels are displayed as fold differences relative to the control cells 
[vehicle (control buffer only)-treated OSC-20, OSC-19 and HOC313 cells, 
respectively]. Each data point represents the mean of 3 independent experi-
ments. The vertical bars show standard deviations. Error bars correspond to 
SEM. *P<0.05 vs. control vehicle-treated OSC-20, OSC-19 and HOC313 cells, 
respectively. (D) Relative mRNA expression levels of MMP-13 and PD-L1 
in the DCs co-cultured with HOC313 cell lines treated with tubulin inhibitor 
(HAL, eribulin; PTX, paclitaxel; and VBL, vinblastine). Expression levels are 
displayed as fold differences relative to the control cells (control vehicle-treated 
HOC313 cells). Each data point represents the mean of 3 independent experi-
ments. The vertical bars show standard deviations. Error bars correspond to 
SEM. *P<0.05 vs. control vehicle-treated DCs co-cultured with HOC313 cells.
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the protective effects on invasion and metastasis. The other 
mechanisms behind the protective effects of MMP-9 warrant 
further investigation. All of these results suggest that MMP-7 
and -13 are strong candidate proteinases for involvement in 
the cell surface degradation of PD-L1. As shown in Fig. 3, the 
amount of intact purified PD-L1 was reduced by recombinant 
MMP-13 and -7 following incubation for 24 h at 37˚C. There 
were no digested low-molecular-weight fragments. These 
results suggest that MMP-13 and MMP-7 have cleavage 
activity against PD-L1 and PD-L1 digested at multiple regions 
may be degraded at the PD-1 binding domain. However, the 
issue of which MMP, MMP-13 or MMP-7, is critical for the 
cell surface digestion of PD-L1 is remains unclear.
To define which MMP contributes to PD-L1 degrada-
tion in HNSCC cells, we used MMP inhibitors with different 
specificities. As shown in Fig. 4, as the expression of PD-L1 
was significantly restored by a specific inhibitor of MMP-13 
(CL82198), we hypothesised that MMP-13 was involved in 
the shedding/cleavage of PD-L1 in the OSC-20 cells. The role 
of MMP-7 in the shedding/cleavage of PD-L1 may be minor 
in vitro as the MMP-7 inhibitor, BB94, could not restore cell 
surface PD-L1 expression. MMP-13 may play a protective role in 
melanoma cell lung metastasis as the lung metastases of B16BL6 
melanoma cells were found to be increased in MMP-13 KO 
mice after intravenous injection (44). MMP-2, MMP-7, MMP-9 
and MMP-14 (MT1-MMP) play important roles in the invasion 
and metastasis of cancer cells (39-41). Therefore, the targeted 
deletion of these MMPs may inhibit cancer cell proliferation, 
invasion and metastasis. Indeed, tumourigenesis and metastasis 
are decreased in MMP-2 KO (45), MMP-7 KO (46) or MMP-9 
KO mice (47,48). However, contradictory results have also been 
observed; that is, a protective role of host MMPs in carcinogen-
esis, tumour growth or metastasis, in experiments using MMP-3 
KO (49), MMP-7 KO (48), MMP-9 KO (42,43) and MMP-12 
KO mice (50). In addition, a completely protective role in 
cancer has been reported in MMP-8 KO mice, which exhibited 
enhanced carcinogenesis induced by chemical carcinogens (51). 
Therefore, the data from previous studies suggest that MMP-13 
and some MMPs play dual roles in invasion and metastasis, that 
is, a promoting effect and a protective effect. However, in these 
previous studies, the detailed mechanisms behind the protective 
effects on invasion and metastasis were not fully elucidated. The 
results of this study suggest that the shedding/cleavage of PD-L1 
by MMP-13 may be one of the mechanisms behind the protec-
tive effects on invasion and metastasis. Further in vivo studies 
are required to test and confirm this hypothesis.
As shown in Fig. 5, only paclitaxel treatment upregulated 
MMP-13 expression in HOC313 cells compared with the other 
tubulin inhibitors tested. No tubulin inhibitor used to treat the 
OSC-20 and OSC-19 cells increased MMP-13 expression. In 
a previous study, we determined the in vitro anti-proliferative 
activities in eribulin-treated OSC-20, OSC-19 and HOC313 
cells (52). Of note, the HOC313 cells were highly sensitive to 
eribulin compared with other cell lines. Previously, another 
group of researchers demonstrated that the reduced expres-
sion levels of 4 tubulins (TUBA1C, TUBA4A, TUBB3 and 
TUBB6) was significantly associated with eribulin sensitivity 
and that the expression of one tubulin (TUBB2A) was signifi-
cantly associated with paclitaxel sensitivity (53). The tubulin 
inhibitors are broadly classified into microtubule-stabilizing 
(such as paclitaxel) and microtubule-destabilizing (such as 
vinblastine and eribulin) drugs (54). SMAD proteins, which 
are essential mediators of the TGF-β signalling pathway, 
normally bind microtubules (55). SMAD signalling plays an 
important role in promoting the invasive phenotype of human 
HNSCC cells by upregulating their MMP-13 expression (56). 
These data suggest that the expression profiles of tubulins may 
differ among the OSC-20, OSC-19 and HOC313 cells, and that 
tubulin inhibitors may stabilise or destabilise the association 
between SMAD proteins and microtubules in OSC-20, OSC-19 
and HOC313 cells, consequently resulting in the differential 
induction of MMP13 expression. However, we cannot exclude 
the possibility that paclitaxel may target other molecules to 
upregulate MMP-13 expression.
Although anti-PD-1 treatment can produce durable 
responses, it appears to benefit only a subset of patients. If 
anti-PD-1 therapy alone were not so effective, it would be 
appropriate to combine this approach with another therapeutic 
option' to aid readability. However, at present, no candidate 
drugs for such a combination therapy are known. In this study, 
we demonstrated that MMP-13 may play a critical role in the 
shedding/cleavage of PD-L1. In addition, among the anticancer 
drugs generally used in the treatment of head and neck cancer 
patients, paclitaxel increased MMP-13 expression in R/M 
HNSCC cells (HOC313 cells) co-cultured without/with DCs. 
These results suggested that paclitaxel is a strong candidate 
for use in combination with anti-PD-1 therapy. Clearly, further 
in vivo studies are required to test this hypothesis.
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